Viewing data from:

RIVASTIGMINE TARTRATE

ANDA

RIVASTIGMINE TARTRATE | A077130 | DR REDDYS LABORATORIES INC

4 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-10-21 | 9 NDCs

Highest NADAC/Unit

$0.1706

per ea

Lowest NADAC/Unit

$0.1584

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
55111035460RIVASTIGMINE 4.5 MG CAPSULE	$0.1706	EA	Generic	—	2026-10-21
55111035405RIVASTIGMINE 4.5 MG CAPSULE	$0.1706	EA	Generic	—	2026-10-21
60687077701RIVASTIGMINE 1.5 MG CAPSULE	$0.1681	EA	Generic	—	2026-10-21
55111035260RIVASTIGMINE 1.5 MG CAPSULE	$0.1681	EA	Generic	—	2026-10-21
55111035205RIVASTIGMINE 1.5 MG CAPSULE	$0.1681	EA	Generic	—	2026-10-21
55111035305RIVASTIGMINE 3 MG CAPSULE	$0.1626	EA	Generic	—	2026-10-21

Showing 6 of 9 NDCs.

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain12 active DMFs5 inactive

11 active API suppliers hold Drug Master Files for this ingredient.

CIPLA LTDRIVASTIGMINE TARTRATE USP

DMF 170642003

SUN PHARMACEUTICAL INDUSTRIES LTDRIVASTIGMINE TARTRATE USP

DMF 172892004

ERREGIERRE SPARIVASTIGMINE TARTRATE

DMF 202272007

ORBION PHARMACEUTICALS PRIVATE LTDRIVASTIGMINE TARTRATE

DMF 207532007

ALEMBIC PHARMACEUTICALS LTDRIVASTIGMINE TARTRATE USP

DMF 218002008

APOTEX INCRIVASTIGMINE TARTRATE

DMF 222522008

APITORIA PHARMA PRIVATE LTDRIVASTIGMINE TARTRATE USP (NON-STERILE DRUG SUBSTANCE)

DMF 240862010

MACLEODS PHARMACEUTICALS LTDRIVASTIGMINE TARTRATE

DMF 241532010

JUBILANT PHARMOVA LTDRIVASTIGMINE TARTRATE

DMF 245012011

MSN ORGANICS PRIVATE LTDRIVASTIGMINE TARTRATE USP [ROUTE CODE "RM"]

DMF 280732014

MSN ORGANICS PRIVATE LTDRIVASTIGMINE TARTRATE USP

DMF 357762021

WUXI FORTUNE PHARMACEUTICAL CO LTDRIVASTIGMINE TARTRATE

DMF 408302025

EXCELLA GMBHInactiveRIVASTIGMINE TARTRATE

DMF 214692008

EMCURE PHARMACEUTICALS LTDInactiveRIVASTIGMINE TARTRATE

DMF 222492008

INTERQUIM SAInactiveRIVASTIGMINE TARTRATE

DMF 227732009

ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTDInactiveRIVASTIGMINE TARTRATE

DMF 233462009

MYLAN LABORATORIES LTDInactiveRIVASTIGMINE TARTRATE USP

DMF 244422010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Nov 8, 2007	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — EQ 1.5MG BASE

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Oct 31, 2007

No patent or exclusivity listings for this strength.

#002 — EQ 3MG BASE

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Oct 31, 2007

#003 — EQ 4.5MG BASE

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Oct 31, 2007

#004 — EQ 6MG BASE

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Oct 31, 2007